Mitsubishi UFJ Trust & Banking Corp Sells 2,173 Shares of Labcorp Holdings Inc. $LH

Mitsubishi UFJ Trust & Banking Corp cut its holdings in Labcorp Holdings Inc. (NYSE:LH) by 6.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,485 shares of the medical research company’s stock after selling 2,173 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Labcorp were worth $8,401,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LH. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Labcorp during the fourth quarter worth about $26,000. JPL Wealth Management LLC acquired a new stake in shares of Labcorp in the 3rd quarter valued at approximately $28,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp during the 4th quarter valued at approximately $29,000. Motco acquired a new position in Labcorp during the 3rd quarter worth approximately $32,000. Finally, Beacon Financial Strategies CORP acquired a new position in Labcorp during the 4th quarter worth approximately $33,000. Institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling

In related news, EVP Jonathan C. Meltzer sold 87 shares of Labcorp stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president directly owned 2,782 shares of the company’s stock, valued at $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the sale, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 16,113 shares of company stock worth $4,547,450. Corporate insiders own 0.84% of the company’s stock.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q1 results beat Street estimates — EPS of $4.25 vs. $4.09 est. and revenue of $3.54B vs. $3.51B, with revenue up ~5.8% year?over?year. Management pointed to broad segment growth driving the beat. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
• Positive Sentiment: Raised FY2026 guidance — EPS guidance range set to $17.70–$18.35 and revenue guidance roughly $14.7B–$14.8B, reflecting steady diagnostics demand that management says supports continued growth. Labcorp raises full-year forecasts on steady diagnostics demand
• Positive Sentiment: Analyst reaction was initially favorable — outlets noted pre?market gains after the beat and the raised view, signaling positive near?term sentiment from some desks. LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper review (slides, PR, and call transcript). Useful for investors who want line?by?line detail on margins, segment trends and cadence. Labcorp Holdings Inc. 2026 Q1 – Results – Earnings Call Presentation Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Longer?term valuation context: coverage pieces highlight LH as a value/quality name given its margin profile and ROE, which may attract income/value investors. Here’s Why Labcorp Holdings (LH) is a Strong Value Stock
• Negative Sentiment: Market reaction turned muted/negative intraday — reasons include guidance that is only modestly above consensus (company range roughly in line with Street forecasts), possible profit?taking after the beat, and limited incremental upside in margin guidance. This helps explain why the stock is down despite the beat. Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Robert W. Baird set a $334.00 target price on shares of Labcorp in a research report on Friday. JPMorgan Chase & Co. upped their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Finally, Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and an average target price of $308.00.

Labcorp Trading Down 0.2%

Shares of NYSE LH opened at $256.37 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.23 and a current ratio of 1.73. Labcorp Holdings Inc. has a 52-week low of $239.67 and a 52-week high of $293.72. The firm has a 50 day moving average price of $270.69 and a two-hundred day moving average price of $267.42. The stock has a market cap of $21.07 billion, a P/E ratio of 22.71, a price-to-earnings-growth ratio of 1.73 and a beta of 0.91.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. Labcorp’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s dividend payout ratio is presently 27.53%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.